Business Wire

Aqua Comms, Bulk Fiber Networks and Meta Complete Construction of the Havhingsten Cable System

Share

Aqua Comms, a leading provider of network connectivity services, Bulk Fiber Networks, a leading builder and operator of fiber network infrastructure, and Meta have completed the construction of the Havhingsten cable system. A fully funded project, the parties have contracted with Alcatel Submarine Networks (“ASN”) to build the subsea cable, which will bring greater connectivity in Europe and the Nordics.

This new route represents true diversity avoiding congested paths across the English Channel and offers resilient network architecture options for enterprises, carriers and hyperscalers whilst delivering the lowest latency available between Dublin and the Nordic region.

The Havhingsten cable system showcased several key innovations and technological milestones throughout its design and construction.

Firstly, Havhingsten is the world’s first aluminum conductor powered subsea cable system. As a material, aluminum allows for a much lower cable conductor voltage drop, which ultimately allows for a higher number of fiber pairs per cable. To achieve such innovative solutions requires investment in technology and close collaboration with partners and vendors. The removal of traditional copper raw material and replacement with aluminum from the manufacturing process benefits the overall system in efficiency and cost reduction, as copper is associated with variable availability and higher price. Additional benefits include, lighter aluminum allows more cable to be loaded onto an installation vessel and improved resistance to hydrogen penetration, an element which is unfavorable to the operation of optical fiber in ocean waters.

Secondly, the end-to-end system combines data transmission seamlessly across both an unrepeatered subsea segment in the Irish Sea, a terrestrial segment in the UK and a repeatered segment in the North Sea. Typical systems have one or two of these elements, but not all three.

Lastly, the system utilized a new enhanced, jet-assisted burial plough in both the North and Irish Sea segments, allowing the installers of the system to bury the cable to our specific demanding level of protection in very challenging seabed conditions along the route.

About Aqua Comms:

Aqua Comms is a leading provider of global subsea connectivity services delivered through an extensive portfolio of owned and operated subsea systems. Aqua Comms offers connectivity networking solutions including managed capacity services, spectrum and dark fibre to the global content, cloud and carrier markets.

To learn more about Aqua Comms and its portfolio of connectivity networking solutions visit www.aquacomms.com

In April 2021, Aqua Comms DAC was acquired by Digital 9 Infrastructure plc (D9), an LSE listed investment trust managed by Triple Point Investment Management LLP.

D9 is a digital infrastructure investment trust that has raised over US$ 1.1 billion since its IPO in March 2021, investing into data centres and fibre networks. Its team has over US$ 300 billion transactional and operational experience in digital infrastructure. The number 9 in Digital 9 Infrastructure comes from the UN Sustainable Development Goal number 9, which focuses the fund on investments that bridge the digital divide by increasing connectivity globally and that improve the environmental sustainability of digital infrastructure.

To learn more about D9 visit www. https://www.d9infrastructure.com

About Bulk Fiber Networks

Bulk Fiber Networks is a leading builder and operator of fiber network infrastructure, tailor-made to meet the growing demands of large-scale data and cloud service providers in the Nordics, the US and Europe. We offer some of the shortest, lowest-latency international and intra-Nordic fiber routes available. To learn how Bulk Fiber Networks can help you connect into the Nordics, visit bulkinfrastructure.com and follow us on LinkedIn, Twitter and Facebook. Bulk Fiber Networks is a division of Bulk Infrastructure, a leading provider of sustainable digital infrastructure in the Nordics.

About Meta

Meta builds technologies that help people connect, find communities, and grow businesses. When Facebook launched in 2004, it changed the way people connect. Apps like Messenger, Instagram and WhatsApp further empowered billions around the world. Now, Meta is moving beyond 2D screens toward immersive experiences like augmented and virtual reality to help build the next evolution in social technology.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

iMiller Public Relations
Ilissa Miller
bulk@imillerpr.com
+1 866-307-2510

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Takeda and Seagen to Highlight ADCETRIS ® Combination Data Showing Statistically Significant Improvement in Overall Survival (OS) for Patients with Advanced Hodgkin Lymphoma26.5.2022 23:25:00 CEST | Press release

Takeda Pharmaceutical Company Limited (TSE:4502) and Seagen Inc., (NASDAQ:SGEN) today announced that overall survival (OS) data from the Phase 3 ECHELON-1 clinical trial of an ADCETRIS® (brentuximab vedotin) plus chemotherapy combination will be presented in an oral session at the 59th American Society of Clinical Oncology (ASCO) Annual Meeting on Friday, June 3, 2022, 1:00-4:00 PM CT, and at the 27th European Hematology Association (EHA) Annual Meeting on Friday, June 10, 2022, 11:30 – 12:45 CEST. “The longer-term follow-up data from the ECHELON-1 trial have significant clinical importance, as this trial represents one of only two frontline randomized studies in advanced stage Hodgkin lymphoma that shows an overall survival advantage for the experimental arm,” said Stephen Ansell, M.D., Ph.D., Mayo Clinic, and ECHELON-1 study investigator. “These results clearly show that the addition of brentuximab vedotin to chemotherapy improves the long-term outcome of patients and the combination

Ipsen: ASCO 2022: New Cabometyx ® Data Show Encouraging Results in Monotherapy and in Combination Across Different Tumor Types Including Metastatic Non-Small Cell Lung Cancer26.5.2022 23:00:00 CEST | Press release

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY) today announced encouraging data to be presented for the multi-targeted tyrosine kinase inhibitor (TKI), Cabometyx® (cabozantinib), across a range of cancer types at this year’s American Society of Clinical Oncology Annual Meeting (ASCO 2022) to be held on 3-7 June. Data presentations will include findings in metastatic non-small cell lung cancer (NSCLC), as well as established indications of advanced renal cell carcinoma and radioactive iodine-refractory differentiated thyroid cancer (RAI-R DTC). These data show that the therapeutic potential of Cabometyx as a key treatment option in a broad range of tumors is continuing to be realized. Updated outcomes from the multicenter Phase Ib COSMIC-021 trial evaluating the combination of Cabometyx plus atezolizumab in an expanded patient population in metastatic NSCLC demonstrate encouraging clinical activity with manageable toxicity in people previously treated with an immune checkpoint inhib

New Better Dispensing Videos from Nordson EFD Explain Jetting Technology and How to Choose the Right Solution26.5.2022 19:00:00 CEST | Press release

Nordson EFD, a Nordson company (NASDAQ: NDSN) and leading precision fluid dispensing systems manufacturer, introduces a new Better Dispensing™ How-To Video series. These three highly educational videos presented by EFD application specialist, Tom Muccino, provide best practices for choosing between contact dispensing and non-contact (jet) dispensing, and how to select the best jetting valve for a manufacturing application. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220510006079/en/ xQR41 Series MicroDot™ needle valve (left) and PICO Pµlse XP jet valve (right). (Photo: Business Wire) “One of the main differences is that with jetting, your valve never touches the surface of the part. Instead, your fluid “flies” or “jets” out of the valve, which is above the part,” Muccino explains in the first video. “This makes jetting perfect for fragile or complex parts.” Nordson EFD provides a wide range of contact and non-contact (jet

Medisca Drives Worldwide Access to Thyroid through Distribution License with SUANFARMA26.5.2022 18:17:00 CEST | Press release

On March 16, 2022, Medisca, a global supplier of pharmaceutical ingredients and equipment, entered into an exclusive agreement with SUANFARMA, a European-based manufacturer and distributor of pharmaceutical ingredients, for the global supply and distribution of Thyroid Powder, USP, by leveraging its exclusive partnership with pharmaceutical manufacturer, Sichuan Deebio Pharmaceutical Co., Ltd (Deebio). “Partnering with Deebio in June 2021 was a huge milestone for the pharmaceutical compounding industry as it allowed us to secure and stabilize the supply of high quality Thyroid Powder for the US market,” said Panagiota Danopoulos, Senior Vice President of Global Strategy & Innovation at Medisca. “After going to market, we immediately realized that the demand for Thyroid Powder extended outside of our usual distribution channels to compounding pharmacies,” continued Danopoulos. “And we had the capacity to upscale supply to make this critical ingredient accessible to various markets, chan

Merck to Present Latest Research From Oncology Portfolio at ASCO 202226.5.2022 18:00:00 CEST | Press release

Merck, a leading science and technology company, today announced the latest research representing the Company’s innovative oncology portfolio has been accepted for presentation at this year’s American Society of Clinical Oncology (ASCO) Annual Meeting, June 3-7, 2022. Data encompass Company-sponsored, investigator-sponsored, and external collaboration studies. Abstracts to be shared at the meeting include data for the Company’s licensed medicines BAVENCIO® (avelumab), TEPMETKO® (tepotinib) and ERBITUX® (cetuximab), and its oncology pipeline. The presentations span key tumor types including advanced urothelial carcinoma (UC), advanced renal cell carcinoma (RCC), metastatic non-small cell lung cancer (NSCLC), metastatic colorectal cancer (CRC), and head and neck cancer (SCCHN). “We look forward to coming together with the scientific community at ASCO 2022, where we will share the latest data from our portfolio, which demonstrate our determination to make a real difference in the lives of

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom